Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Dulbecco's Modified Eagle's Medium - high glucose (DME) from Sigma-Aldrich
...r routine procedures. Hollandes contains formaldeh...l decalcify small bone specimens. Tissue that is f...ith most stains, and the cupric acetate in the sol...nophil and endocrine cell granules so that less ly...
...tograph/Mass Spectrometer, utilizing many of the h...igh throughput and excellent productivity, providi...io. Like the GCMS-QP2010 Plus, the GCMS-QP2010s fe...um separation, 20 temperature ramps, and both scan...
Biology Products:(Date:11/26/2009)...IDGE, Mass. (November 26, 2009) Whitehead researc...or human cells to pinpoint specific genes and prot...n Science . , In most human cell cultures genes... father and one from the mother. Gene inactivation... one copy is inactivated, the second copy usually ...
(Date:11/26/2009)...(methicillin-resistant Staphylococcus Aureus ) an...ation as low-temperature plasma prototype devices ... unfailing bactericidal cocktails. , Two prototy...disinfection of healthy skin (e.g. hands and feet)... pose a lethal threat; and another to shoot bacter...
(Date:11/25/2009)...in, a hormone produced in the stomach, may be used...of Parkinson,s disease, Yale School of Medicine re...issue of the Journal of Neuroscience . , Parkin...ine neurons in an area of the midbrain known as th...ine production. Reduced production of dopamine in...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Hormone ghrelin can boost resistance to Parkinson's disease 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 1Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 3Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 4Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 5Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 6Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 7Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 8Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 9Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 10Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 11Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 12Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 13Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 14Retail Health Clinics The Real Story 59443 1Retail Health Clinics The Real Story 59443 2Pajama Program Launches 2009 2010 Awareness 26amp 3B Fundraising Campaign 3A A BETTER BEDTIME 59441 1Pajama Program Launches 2009 2010 Awareness 26amp 3B Fundraising Campaign 3A A BETTER BEDTIME 59441 2Pajama Program Launches 2009 2010 Awareness 26amp 3B Fundraising Campaign 3A A BETTER BEDTIME 59441 3Pajama Program Launches 2009 2010 Awareness 26amp 3B Fundraising Campaign 3A A BETTER BEDTIME 59441 4(Date:11/30/2009)...0 Novavax, Inc. (Nasdaq:...ed today that the company will be presenting at th...ber 2, 2009 at 12:30 pm local time at The New York...ew of the company,s business strategy, research an... link to the live audio only presentation can be a...
(Date:11/30/2009)...wire/ -- Dr. Jessica Torrente, Assistant Professor...cal Center in Washington, D.C., demonstrated the i...g (BSGI) in clinical practice as an adjunct imagin...y at the annual meeting of the Radiological Societ...he exhibit was to demonstrate how BSGI is used in ...
(Date:11/30/2009)... BioMarin Pharmaceutical ...d and Drug Administration (FDA) has granted orphan...), amifampridine phosphate, for the rare autoimmun.... 3,4-DAP has previously received orphan drug des...ommittee for Medicinal Products for Human Use of t...
(Date:11/30/2009)..., Nov. 30 Exiqon A/S (NASDAQ OMX C... Medical School ICCB-Longwood Screening Facility (...g Center of Excellence. ICCB-L supports investiga...pitals and institutions, for high-throughput scree...icroRNAs are a novel class of small, non-coding RN...
Breaking Biology Technology:NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3